Ultragenyx Pharmaceutical Inc. (RARE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on January 11, 2021, by Ultragenyx Pharmaceutical Inc. The filing primarily serves to disclose preliminary unaudited fiscal year 2020 revenue for the product Crysvita, cash and investment positions at the end of fiscal 2020, and revenue guidance for Crysvita for the 2021 fiscal year. The Company expects to report full-year 2020 results in February 2021.
Key Financial Metrics
The filing text references the announcement of preliminary unaudited fiscal year 2020 revenue for Crysvita and cash and investments at the 2020 fiscal year end. However, the specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity are not contained within the body of this Form 8-K document; they are referenced as being detailed in the attached Press Release (Exhibit 99.1).
Material Changes
The filing does not provide specific comparative data or material changes versus the prior period within the text itself. It notes the issuance of a press release containing these preliminary figures and guidance.
Guidance, Outlook, and Management Commentary
- Guidance: The Company issued 2021 revenue guidance for Crysvita in its territories.
- Outlook: Full-year 2020 results are scheduled for release in February 2021.
- Management Commentary: Management posted a presentation to the Company website for the 39th Annual J.P. Morgan Healthcare Conference scheduled for January 12, 2021.
- Risks and Contingencies: The filing includes standard disclaimers that the information in the press release and presentation is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for the specific preliminary 2020 Crysvita revenue figures.
- Verify the exact cash and investment balances at the end of fiscal 2020 in the attached press release.
- Confirm the specific 2021 revenue guidance numbers for Crysvita provided in the press release.
- Access the presentation posted on the Company website for additional details presented at the J.P. Morgan Healthcare Conference.
- Monitor the February 2021 filing for the full audited fiscal year 2020 results.